ARMP - AMEX
Armata Pharmaceuticals, Inc.
$7.92
-4.2%Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
At a Glance
Live SnapshotArmata Pharmaceuticals, Inc. Management Team
Dr. Pierre Kyme Ph.D.
Chief Business Officer
Compensation
$733,062
Dr. Deborah L. Birx M.D.
Chief Executive Officer & Director
Compensation
$554,998
Ms. Bani Tchekanova Ph.D.
Head of Regulatory Strategy & Operations
Mr. David D. House
Senior Vice President of Finance & Principal Financial Officer
Compensation
$352,231
Mr. Peter Hubbard
Vice President of Operations
Armata Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, there has been no insider trading activity reported for ARMP.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
No insider trading activity reported. This could indicate blackout periods, lack of conviction, or regulatory restrictions.
Insider Participation
No insider trading activity reported from any insiders in the past year.
SEC Filings
ARMP - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | June 11, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 12, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | June 12, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | August 03, 2023 | September 14, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | October 17, 2022 | November 16, 2022 | 2022 | |
DEF 14A DEF 14A 2022 N/A | March 09, 2022 | March 30, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 21, 2021 | June 07, 2021 | 2021 | |
DEF 14A DEF 14A 2021 N/A | February 26, 2021 | March 16, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | October 22, 2020 | December 08, 2020 | 2020 | |
DEF 14A DEF 14A 2020 N/A | March 06, 2020 | March 26, 2020 | 2020 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.